Bridgebio Pharma, Inc. · NASDAQ:BBIO
Bridgebio Pharma — J.P. Morgan Healthcare Conference 2025
35 slides from Bridgebio Pharma's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Presentation
J.P. Morgan Presentation January 13, 2025
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sectio
Slide 3: Key recent achievements: clinical impact
Key recent achievements: clinical impact 3
Slide 4: Key recent achievements: 3 fully enrolled Phase 3 trials
Key recent achievements: 3 fully enrolled Phase 3 trials NEW INFORMATION Trial enrolled 112 patients to evaluate BBP-418 in Limb-Girdle Muscular Dystrophy 2I/R9 Trial enrolled 70 participants to evaluate encaleret in Autosomal Dominant Hypocalcemia Type 1 Trial enrolled 114 participants to evaluate
Slide 5: Key recent achievements: regulatory advancement for late-stage programs
Key recent achievements: regulatory advancement for late-stage programs Receives Breakthrough Infigratinib Designation (BTD) for Achondroplasia Receives Rare Pediatric Disease BBP-418 Designation (RPDD) for Limb- Girdle Muscular Dystrophy 2I/R9 Receives Regenerative Medicine BBP-812 Advanced Therapy
Slide 6: Key recent achievement: Attruby regulatory approval
Key recent achievement: Attruby regulatory approval Indicated for the treatment of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization 6
Slide 7: Remarkable commercial momentum: Attruby Scripts
Remarkable commercial momentum NEW INFORMATION 430 Attruby Scripts 7
Slide 8: BridgeBio's growth is underpinned by an innovative corporate model
BridgeBio’s growth is underpinned by an innovative corporate model, as highlighted in a recent publication Applications of Portfolio Theory to Accelerating Biomedical Innovation Neil Kumar, Andrew W. Lo, Chinmay Shukla, and Brian Stephenson Diversified portfolio Operational nimbleness World class, d
Slide 9: The BridgeBio ecosystem has a dynamic pipeline of products
The BridgeBio ecosystem has a dynamic pipeline of products Pre- Patients Market Estimated Program Indication Phase 1 Phase 2 Phase 3 Approved clinical (US + EU) Oppty US LOE** ✓ Attruby Transthyretin Amyloidosis 500,000+ $20B+ 2039 (acoramidis) (ATTR-CM) Fully Achondroplasia (ACH) 55,000+ $2B+ 2041
Slide 10: Attruby
6 Attruby (acoramidis) as+mgtablet
Slide 11: ATTR is a multi-billion-dollar market primed for continued expansion
ATTR is a multi-billion-dollar market primed for continued expansion Global annual ATTR market sales1 $B $15-$202 Market growth drivers include: • With more sponsors, $6.4 there is expanding disease awareness +57% $4.3 • Increased global $3.2 adoption of non- $2.6 invasive diagnostic $1.7 tools $0.7
Slide 12: The way we win
The way we win 1 2 Compelling Market Access: Clinical Data + Make it Easy 12
Slide 13: Key Data
1 Key Data The most rapid benefit seen in any 3 Months Phase 3 study of ATTR-CM to date In composite of all-cause mortality 42% Reduction and recurrent cardiovascular-related hospitalization events at Month 30 In the cumulative frequency of 50% Reduction cardiovascular-related hospitalization events
Slide 14: Data: Attruby achieved near-complete stabilization of TTR
1 Data: Attruby achieved near-complete stabilization of TTR Increase in serum TTR levels reflect in vivo stabilization “Change from baseline in serum TTR levels were higher in participants receiving acoramidis only than those receiving placebo+tafamidis at Month 30...”1 Evidence of potency on TTR st
Slide 15: Make it easy: simplified, differentiated, generous access programs
2 Make it easy: simplified, differentiated, generous access programs 28-day supply for patients new to Attruby Free Trial (newly diagnosed or switching from another therapy) Distribution Independent and rare/orphan disease–focused Specialty Pharmacies (SPs) Network where Institutional SPs can keep p
Slide 16: Performance to date indicates strong commercial momentum
Performance to date indicates strong commercial momentum 430 248 77% Attruby scripts Unique Medicare lives in equal written to date prescribing HCPs formulary position to tafamidis 16
Slide 17: Positive feedback all around on Market Access
Positive feedback all around on Market Access: Pricing: ForgingBridges: “ You priced responsibly and have a good label; we will have you at parity with tafamidis. Also, I have never seen a company offer free drug to their trial patients. Shows commitment.” - Payer the health system's mission of putt
Slide 18: Our Attruby team has experienced industry leaders who have built and launched blockbuster drugs
Our Attruby team has experienced industry leaders who have built and launched blockbuster drugs Matt Outten Julie Everett John Whang Chief Commercial Officer Chief Business Officer Chief Medical Affairs Officer • Broad commercial leadership expertise with success • Successfully led cross-functional
Slide 19: Looking Ahead: Attruby Delivers Outstanding Results in Patients with Poor Prognosis
Looking Ahead: Attruby Delivers Outstanding Results in Patients with Poor Prognosis Natural History ATTRibute-CM mITT Population V122I ATTRv-CM has an aggressive Statistically significant benefit on composite ACM or phenotype and poor prognosis1 first CVH in ATTRv-CM participants vs. placebo2 60 Med
Slide 20: Additional data: Elevated TTR levels are associated with improved survival
Additional data: Elevated TTR levels are associated with improved survival Genetic stabilization of transthyretin associated with Higher TTR concentration associated with improved health outcomes (N≈69K individuals)1 greater life expectancy (N≈102K individuals)2 - WT - T119M Carriers Hazard ratio (9
Slide 21: Infigratinib
Infigratinib
Slide 22: Infigratinib is an oral best-in-class FGFR3 inhibitor
Infigratinib is an oral best-in-class FGFR3 inhibitor that targets achondroplasia and hypochondroplasia at their source Impact Opportunity Design Criteria Phase 2 Data 55,000+ People Annualized height velocity Target FGFR3-driven skeletal (To the sponsor’s knowledge, dysplasias at their source In th
Slide 23: We have fully enrolled a Phase 3 study (PROPEL 3) of Infigratinib in Achondroplasia
We have fully enrolled a Phase 3 study (PROPEL 3) of Infigratinib in Achondroplasia with LPLV in 2H 2025 0.25 mg/kg/day Infigratinib (N ~ 76) Open Label Screening and Extension Observational Period Randomization Children are Children are followed 2:1 followed until for a minimum of 6 (N = 114) adult
Slide 24: BBP-418
ie) ei + BBP-
Slide 25: BBP-418 is a first-in-class, disease-modifying therapy for LGMD
BBP-418 is a first-in-class, disease-modifying therapy positioned to be the first approval in any form of limb-girdle muscular dystrophy Impact Opportunity Design Criteria Phase 2 Data Targets the LMGD2I/R9 at its Glycosylated αDG source by adding substrate to (Expected surrogate endpoint) 7,000+ Pa
Slide 26: We have fully enrolled a Phase 3 study (FORTIFY) of BBP-418 in LGMD2I/R9
We have fully enrolled a Phase 3 study (FORTIFY) of BBP-418 in LGMD2I/R9 and expect topline interim analysis data readout in 2H 2025 BBP-418 (N ~ 75) BBP-418 (N ~ 75) Screening Interim • Genetically Analysis Randomization Open Label confirmed, 2:1 (N ~ 112) Extension symptomatic Topline Data LGMD2I/
Slide 27: Encaleret
~ oO t= a © (S] c Lu
Slide 28: Encaleret is a first-in-class, disease-modifying investigational therapy for ADH1
Encaleret is a first-in-class, disease-modifying investigational therapy with potential to be the first approved intervention for ADH1 Impact Opportunity Design Criteria Phase 2 Data 25,000+ Patients Target ADH1 at its source by Serum calcium to normal In the US/EU with ADH1, a genetic range desensi
Slide 29: We have fully enrolled the Phase 3 study (CALIBRATE) of encaleret in ADH1
We have fully enrolled the Phase 3 study (CALIBRATE) of encaleret in ADH1 and expect topline results in 2H 2025 Screening and SoC Encaleret Optimization Period Encaleret Titration Period (N ~ 47) Maintenance Period • Age > 16 years of age SoC Long-Term • Documented pathogenic Maintenance Extension R
Slide 30: BBP-812 Canavan Disease
BBP-812 Canavan Disease
Slide 31: BBP-812 has the potential to change the disease trajectory for children with Canavan
BBP-812 has the potential to change the disease trajectory for children with Canavan, a severe, ultra-rare, autosomal recessive leukodystrophy “One patient in particular is sitting independently and taking steps and walking, and that is certainly Preliminary Data something I’ve never seen with Canav
Slide 32: BridgeBio Ecosystem Highlights
BridgeBio Ecosystem Highlights
Slide 33: BBOT has progressed two potentially first-in-class molecules into the clinic
BBOT has progressed two potentially first-in-class molecules into the clinic with a third expected in 1H 2025 Program Mechanism of Action Status • First direct inhibitor of KRASG12C ON BBO-8520 • Inhibits both KRASG12C GTP (active) and GDP (inactive) states Enrolling KRASG12C ON / OFF • Differentiat
Slide 34: The GondolaBio pipeline features a diverse set of programs across TAs
The GondolaBio pipeline features a diverse set of programs across TAs Lead IND Est. Patient Pop. Indication Discovery Phase 1 Optimization Enabling (US + EU) Erythropoietic Protoporphyria (EPP) 20k Galactosemia 10k Alpha-1 Antitrypsin Deficiency (AATD) 200k Neurofibromatosis Type 1 (NF1) 200k Heredi
Slide 35: We are well-financed and expect to hit numerous milestones in 2025
We are well-financed and expect to hit numerous milestones in 2025 1H 2025 2H 2025 ▪ Q2 and Q3 Earnings Calls ▪ Acoramidis: EU approval ▪ Encaleret: LPLV, Topline ▪ Acoramidis: Japan approval ▪ BBP-418: LPLV, Topline ▪ Q1 Earnings Call ▪ Infigratinib: LPLV De-risked PYS Lives impacted vision for 203
BridgeBio Pharma — J.P. Morgan Healthcare Conference 2025 on 6ix